Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Viz.ai raises $100-million in Series D round

Closely-held Viz.ai raised $100-million to expand its artificial-intelligence platform designed to detect and triage strokes, heart attacks and aneurysms by scanning patient imagery. The Series D funding round led by...

April 6, 2022

Developments

Cannabotech partners with go NXT LVL to make oncology products in California

Closely-held Cannabotech of Israel entered a new strategic partnership with go NXT LVL of California to develop and manufacturing Cannabotech’s oncology products at go NXT LVL’s facilities in accordance with the...

April 6, 2022

Developments

Australian committee approves Claritas Phase 1 trial of R-107

The Australian Human Research Ethics Committee has approved Claritas Pharmaceuticals’ (TSXV:CLAS; OTC:CLAZF) submission for the Phase 1 clinical study of R-107 to be conducted at Scientia Clinical Research in Sydney...

April 5, 2022

Executive Moves

MindMed names Dr. Francois Lilienthal as CCO

Francois Lilienthal Mind Medicine (NASDAQ, NEO:MNMD) appointed Francois Lilienthal, M.D., as chief commercial officer to support the advancement of the company’s clinical development programs. Dr. Lilienthal has...

April 5, 2022

Executive Moves

RNA Disease Diagnostics adds chief scientific advisor, president to board

Dipanjan Pan RNA Disease Diagnostics (RNADD) appointed its chief scientific advisor, Prof. Dipanjan Pan, Ph.D., and company president, John Erickson, Jr., to the board to further position RNADD to execute the next...

April 4, 2022

Markets

BTIG starts Gracell at buy; PT $18

BTIG initiated coverage of Gracell Biotechnologies (NASDAQ:GRCL) with a “buy” rating and $18 price target, “with upside potential driven by value inflection points in the next 12-to-24 months.” The stock closed at $2.33...

April 4, 2022

Developments

Clinigence, Nutex Health complete merger; listing on NASDAQ

Clinigence Holdings (OTC:CLNH) and Nutex Health Holdco completed their business combination. The newly combined company, which will continue under the new name, Nutex Health, brings together two complementary...

April 1, 2022

Markets

Analysts downgrade Silverback; two oncology programs discontinued

Analysts for H.C. Wainwright and SVB Leerink downgraded Silverback Therapeutics (NASDAQ:SBTX) after the company discontinued two leading oncology programs. The stock closed at $3.21 on April 1. The company discontinued...

April 1, 2022

Markets

Cantor cuts Akebia to neutral from OW; PT to $1 from $6

Cantor Fitzgerald downgraded Akebia Therapeutics (NASDAQ:AKBA) to “neutral” from “overweight” and slashed its price target to $1 from $6 after the company received a complete response letter in response to the NDA for...

March 31, 2022

Executive Moves

Sigyn Therapeutics names neurology leader Dr. Ajay Verma to SAB

Ajay Verma Sigyn Therapeutics (OTC:SIGY) appointed Ajay Verma, M.D., Ph.D., a recognized thought leader in the field of neurology, to its scientific advisory board. Dr. Verma’s extensive clinical experience and insights...

March 31, 2022

Markets

Maxim lowers Ayala Pharma PT to $12 from $22

Maxim Group reduced its price target for Ayala Pharmaceuticals (NASDAQ:AYLA) to $12 from $22, but maintained a “buy” rating, after the company discontinued the Phase 2 TENANCITY trial evaluating AL101 in triple negative...

March 30, 2022

Executive Moves

Eric Cheng rejoins Maxim as head of healthcare investment banking

After an absence of five years, Eric Cheng has rejoined Maxim Group as a senior managing director and head of healthcare investment banking. Mr. Cheng held similar titles at Maxim between 2011 and 2017. Mr. Cheng brings...

March 29, 2022

Viz.ai raises $100-million in Series D round

Cannabotech partners with go NXT LVL to make oncology products in California

Australian committee approves Claritas Phase 1 trial of R-107

MindMed names Dr. Francois Lilienthal as CCO

RNA Disease Diagnostics adds chief scientific advisor, president to board

BTIG starts Gracell at buy; PT $18

Clinigence, Nutex Health complete merger; listing on NASDAQ

Analysts downgrade Silverback; two oncology programs discontinued

Cantor cuts Akebia to neutral from OW; PT to $1 from $6

Sigyn Therapeutics names neurology leader Dr. Ajay Verma to SAB

Maxim lowers Ayala Pharma PT to $12 from $22

Eric Cheng rejoins Maxim as head of healthcare investment banking

General

More